Ipamorelin peptide is a synthetic growth hormone-releasing peptide (GHRP) that stimulates the pituitary gland to secrete growth hormone in selective, pulsatile bursts—with minimal effect on cortisol or prolactin. TelosRX evaluates ipamorelin protocols asynchronously through licensed provider review, subject to medical approval by a licensed provider.
Ipamorelin is one of the cleaner GHRPs in the research literature. Where older secretagogues like GHRP-6 drive up cortisol and prolactin alongside GH, ipamorelin mostly sticks to the GH axis. That selectivity is why it's among the most-studied peptides in body composition and recovery research.
It is not FDA-approved. As a compounded peptide, it's prepared under federal compounding regulations and requires evaluation and a provider-issued prescription from a licensed provider.
What Is Ipamorelin?
Ipamorelin is a pentapeptide—a chain of five amino acids—that mimics ghrelin's action at the growth hormone secretagogue receptor (GHSR-1a). It was originally developed in the late 1990s. A 1998 study by Raun et al. in the European Journal of Endocrinology established its selective GH-releasing profile in animal models, showing robust GH pulsatility with minimal cortisol or prolactin stimulation.
It's distinct from GHRH peptides like CJC-1295 or Sermorelin. Those stimulate GH release by binding to growth hormone-releasing hormone (GHRH) receptors. Ipamorelin binds to a different receptor—GHSR—and works through a complementary mechanism. That's why the two classes are often combined in clinical protocols.
How Ipamorelin Works
Here's the GH axis in plain terms: the hypothalamus releases GHRH → the pituitary releases GH → the liver produces IGF-1 → IGF-1 drives downstream tissue-building and metabolic effects. Ipamorelin amplifies the GH pulse from the pituitary by activating GHSR-1a.
The selectivity matters. Unlike GHRP-6 or GHRP-2, ipamorelin produces this GH pulse without significantly stimulating cortisol or prolactin in preclinical models. A 2020 review in Translational Andrology and Urology (PMC7108996) outlined the role of GH secretagogues in body composition management, noting that the selectivity profile of newer GHRPs makes them better candidates for longer-term research protocols compared to their predecessors.
Ipamorelin vs. Other GH Peptides: A Comparison
Understanding how ipamorelin fits relative to other GH-axis peptides helps clarify why it's used as part of stacked protocols.
| Peptide | Receptor Target | GH Effect | Cortisol Impact | Prolactin Impact | Route |
|---|---|---|---|---|---|
| Ipamorelin | GHSR-1a (ghrelin receptor) | Selective GH pulse | Minimal | Minimal | Subcutaneous injection |
| GHRP-6 | GHSR-1a | Strong GH pulse | Notable increase | Notable increase | Subcutaneous injection |
| GHRP-2 | GHSR-1a | Strong GH pulse | Moderate increase | Moderate increase | Subcutaneous injection |
| Sermorelin | GHRH receptor | Moderate GH pulse | Minimal | Minimal | Subcutaneous injection |
| CJC-1295 | GHRH receptor | Sustained GH elevation | Minimal | Minimal | Subcutaneous injection |
| MK-677 | GHSR-1a (oral) | Sustained GH elevation | Minimal | Minimal | Oral |
When stacked with CJC-1295, ipamorelin creates a synergistic effect: CJC-1295 sustains GHRH receptor stimulation while ipamorelin generates a sharp, clean GH pulse through a different receptor pathway. This combination is one of the most-studied in the GH peptide space. See our CJC-1295 + Ipamorelin research guide for the full stack breakdown.
Ipamorelin Benefits: What Research Suggests
Most ipamorelin research uses preclinical animal models. Human clinical trial data is limited but growing. The general findings across studies:
- Body composition: GH elevation from ipamorelin promotes fat metabolism and lean mass support. Research on GH secretagogues broadly shows improvements in body fat percentage and lean mass markers tracked via IGF-1. The downstream effect on lipolysis (fat breakdown) is a primary area of study.
- Sleep quality: GH is predominantly released during slow-wave (deep) sleep. GHRPs including ipamorelin may enhance the GH pulse during this sleep stage when dosed before bed. Controlled trials on this specific endpoint in humans are limited, but preliminary data is encouraging.
- Recovery: GH supports protein synthesis and collagen production. Research on GH axis activation suggests improved recovery times from training stress and injury. Ipamorelin is frequently explored alongside BPC-157 for musculoskeletal recovery protocols.
- IGF-1 elevation: The downstream marker of GH activity is IGF-1. Ipamorelin consistently elevates IGF-1 in preclinical models, and IGF-1 is used clinically to track GH axis activity and guide dosing adjustments in human protocols.
- Bone density: GH and IGF-1 both play roles in bone remodeling. Some research on GH secretagogues explores applications in age-related bone density decline, though evidence in humans remains early-stage.
These are research-level findings, not outcome guarantees. Individual results depend on age, baseline GH and IGF-1 levels, dose, duration, and provider protocol. Compounded ipamorelin is not FDA-approved.
Exploring peptide therapy options? Our MK-677 guide covers a closely related oral GH secretagogue, and our Sermorelin overview covers the GHRH route. All evaluations at TelosRX are conducted asynchronously by licensed providers—no scheduled call required.
Ipamorelin Dosage: Research Context
Clinical research protocols vary significantly. Ipamorelin is typically studied at 200–300 mcg per dose, administered subcutaneously, often timed before sleep to amplify the natural overnight GH pulse or before fasted morning training. Frequency in research ranges from once daily to three times daily depending on protocol goals.
Dosing in any compounded peptide protocol is subject to evaluation and provider-issued prescription. Providers adjust based on baseline IGF-1 levels, age, health status, and individual goals. Do not self-administer based on general research protocols.
Ipamorelin Side Effects: What the Research Notes
Ipamorelin's selective profile means fewer systemic hormonal side effects compared to older GHRPs. The most commonly noted adverse effects in research and clinical use:
- Injection site reactions (redness, mild swelling, temporary discomfort)
- Transient flushing or warmth at injection
- Headache (typically mild and at initiation, often self-resolving)
- Water retention at higher doses or during initial use
- Transient lightheadedness shortly after injection
GH secretagogues can affect insulin sensitivity over extended use. Anyone with diabetes, pre-diabetes, or metabolic syndrome requires closer monitoring under provider care. Prolonged exogenous GH axis stimulation carries theoretical risks including receptor desensitization that require provider oversight. Ipamorelin is not FDA-approved and its long-term safety in human populations has not been established in large controlled trials.
Frequently Asked Questions
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved for any indication. It is available as a compounded peptide through licensed providers who evaluate its use individually. Compounded preparations are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed.
How long does it take for ipamorelin to work?
Most protocols track IGF-1 levels at 4–8 weeks to assess GH axis response. Subjective effects like improved sleep or recovery may be noticed within 2–4 weeks, though this varies by individual. Research protocols for body composition endpoints typically run 12–16 weeks before outcomes are assessed.
Can ipamorelin be stacked with CJC-1295?
Yes—this is one of the most studied combinations in the GH peptide space. CJC-1295 and ipamorelin work at different receptor sites and produce a synergistic GH pulse when combined. See our CJC-1295 + Ipamorelin guide for the full research breakdown.
What does ipamorelin do for sleep?
GH is primarily released during slow-wave sleep. GHRPs like ipamorelin, when timed before sleep, may amplify this natural GH pulse. Some users report improved sleep quality and recovery. Controlled human clinical trial data on this specific endpoint remains limited—it's an active area of research.
How does ipamorelin affect cortisol?
Unlike GHRP-6, ipamorelin shows minimal effect on cortisol in preclinical research. This selectivity is a key reason it's preferred in research protocols where stress hormone elevation is undesirable. Provider monitoring remains important during any GH-axis peptide protocol.
What is IGF-1 and why does it matter for ipamorelin?
IGF-1 (insulin-like growth factor 1) is produced by the liver in response to GH stimulation. It's the primary downstream marker of GH axis activity. Providers use IGF-1 blood testing to confirm GH axis response to ipamorelin and guide dosing adjustments over time. Target IGF-1 ranges vary by age and sex.
Can women use ipamorelin?
Ipamorelin research includes both male and female subjects, though most published studies focus on male populations. Women considering ipamorelin should discuss baseline hormone levels and health status with a licensed provider. As with any compounded peptide, evaluation and approval by a licensed provider is required before use, and protocols are individualized.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.